ACAD
41.57
-0.12
-0.29%
AEMD
6.75
-0.15
-2.17%
APRI
1.87
+0.02
+1.08%
ARNA
4.52
+0.08
+1.80%
ATEC
1.36
-0.03
-2.16%
CNAT
5.02
-0.14
-2.71%
CRXM
0.32
-0.01
-2.02%
CYTX
0.53
-0.018
-3.2505%
DXCM
79.71
+0.35
+0.44%
GNMK
8.97
+0.06
+0.67%
HALO
22.78
+0.68
+3.08%
ILMN
220.51
+0.44
+0.20%
INNV
0.12
0.00
0.00%
INO
7.87
-0.05
-0.63%
ISCO
0.048
+0.005
+10.4651%
ISIS
55.43
-0.7
-1.25%
LGND
98.93
+0.33
+0.33%
LPTN
0.256
-0.019
-6.9793%
MBVX
2.59
-0.12
-4.43%
MEIP
1.74
-0.03
-1.69%
MNOV
3.94
-0.08
-1.99%
MRTX
31.85
+0.55
+1.76%
MSTX
0.462
-0.018
-3.7708%
NBIX
48.32
+1.01
+2.13%
NUVA
47.49
+0.2
+0.42%
ONCS
6.12
-0.23
-3.62%
ONVO
3.73
-0.01
-0.27%
OREX
4.77
+0.01
+0.21%
OTIC
22.06
-0.03
-0.14%
QDEL
22.8
-0.21
-0.91%
RCPT
198.25
+3.34
+1.71%
RGLS
10.32
+0.12
+1.18%
RMD
55.38
+0.07
+0.13%
SCIE
0.015
-0.002
-9.3750%
SPHS
0.8
-0.02
-2.79%
SRNE
17.29
+0.61
+3.66%
TROV
10.1
+0.57
+5.98%
VICL
0.7
0.00
+0.01%
ZGNX
13.03
+0.23
+1.80%
ACAD
41.57
-0.12
-0.29%
AEMD
6.75
-0.15
-2.17%
APRI
1.87
+0.02
+1.08%
ARNA
4.52
+0.08
+1.80%
ATEC
1.36
-0.03
-2.16%
CNAT
5.02
-0.14
-2.71%
CRXM
0.32
-0.01
-2.02%
CYTX
0.53
-0.018
-3.2505%
DXCM
79.71
+0.35
+0.44%
GNMK
8.97
+0.06
+0.67%
HALO
22.78
+0.68
+3.08%
ILMN
220.51
+0.44
+0.20%
INNV
0.12
0.00
0.00%
INO
7.87
-0.05
-0.63%
ISCO
0.048
+0.005
+10.4651%
ISIS
55.43
-0.7
-1.25%
LGND
98.93
+0.33
+0.33%
LPTN
0.256
-0.019
-6.9793%
MBVX
2.59
-0.12
-4.43%
MEIP
1.74
-0.03
-1.69%
MNOV
3.94
-0.08
-1.99%
MRTX
31.85
+0.55
+1.76%
MSTX
0.462
-0.018
-3.7708%
NBIX
48.32
+1.01
+2.13%
NUVA
47.49
+0.2
+0.42%
ONCS
6.12
-0.23
-3.62%
ONVO
3.73
-0.01
-0.27%
OREX
4.77
+0.01
+0.21%
OTIC
22.06
-0.03
-0.14%
QDEL
22.8
-0.21
-0.91%
RCPT
198.25
+3.34
+1.71%
RGLS
10.32
+0.12
+1.18%
RMD
55.38
+0.07
+0.13%
SCIE
0.015
-0.002
-9.3750%
SPHS
0.8
-0.02
-2.79%
SRNE
17.29
+0.61
+3.66%
TROV
10.1
+0.57
+5.98%
VICL
0.7
0.00
+0.01%
ZGNX
13.03
+0.23
+1.80%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.